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Abstract
Recent studies have indicated that injection-related infections such as abscesses and cellulitis
account for the majority of emergency room visits and acute hospitalizations accrued by local
injection drug users. The objective of this analysis was to examine the prevalence and correlates of
developing an abscess among a cohort of injection drug users in Vancouver and to identify socio-
demographic and drug use variables associated with abscesses at baseline. We examined abscesses
among participants enrolled in a prospective cohort of injection drug users. Categorical variables
were analyzed using the Pearson's chi-square test and continuous variables were analyzed using the
Wilcoxon signed rank test. Among 1 585 baseline participants, 341 (21.5%) reported having an
abscess in the last six months. In a logistic regression model that adjusted for all variables that were
associated with having an abscess at p < 0.1 in univariate analyses, female gender [odds ratio (OR)
= 1.7, [95%CI: 1.2 – 2.4]; p = 0.002), recent incarceration (OR = 1.7, [95%CI: 1.3 – 2.2]; p < 0.001),
sex trade involvement (OR = 1.4 [95% CI: 1.0 – 2.0]; p = 0.03), frequent cocaine use (OR = 1.5
[95%CI: 1.2 – 2.0]; p = 0.002) and HIV serostatus (OR = 1.5, [95%CI: 1.2 – 2.0]; p = 0.003) were
positively associated with having an abscess. Explanations for these associations require further
study, and interventions are needed to address this highly prevalent concern.
Findings
The Downtown Eastside of Vancouver, Canada is a com-
munity characterized by high rates of HIV among injec-
tion drug users (IDU), and is also the setting of one of
North America's highest volume needle exchange pro-
gram (NEP) [1]. Recent studies have indicated that injec-
tion-related infections, such as abscesses and cellulitis,
account for the majority of emergency room visits and
acute hospitalizations in local IDU [2,3]. Factors associ-
ated with the development of abscesses among IDU have
not been well described in settings with widespread access
to sterile injecting equipment and high rates of HIV infec-
tion. In particular, abscesses are not characterized in Van-
couver. However, abscesses can lead to serious
complications including but not limited to osteomyelitis
[4], endocarditis [5-7], and septicemia [8,9]. An ongoing
prospective cohort study of IDU in Vancouver allowed for
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having an abscess in this setting.
For these analyses, data was collected through the Van-
couver Injection Drug Users Study (VIDUS), a prospective
cohort that has been previously described in detail [1].
Data from participants who completed baseline question-
naires between May 1, 1996 and May 31, 2004 were eval-
uated for the present study. Participants were categorized
on the basis of whether or not they reported having an
abscess lasting for more than three days during the previ-
ous six months. Univariate and multivariable statistics
were applied to determine factors associated with devel-
oping an abscess in the previous six months. Categorical
variables were analyzed using the Pearson's chi-square
test, and continuous variables were analyzed using the
Wilcoxon signed rank test. Variables associated with hav-
ing an abscess at p < 0.1 were considered in a subsequent
logistic regression analysis.
Socio-demographic and drug-using characteristics consid-
ered in these analyses as potential risk factors included:
age, gender, HIV status, unstable housing, residing in Van-
couver's Downtown Eastside, incarceration in the previ-
ous six months, sex trade involvement, borrowing and
lending of syringes, frequent heroin and cocaine injec-
tion, binge drug use, public drug injection, requiring help
with injections, and methadone maintenance therapy use.
Unstable housing was defined as living in a single room
occupancy hotel, transitional living arrangements, or
being homeless. Individuals who reported injecting
cocaine or heroin once or more a day were defined as fre-
quent heroin and cocaine injectors. Bingeing was defined
as periods in which drugs were injected more often than
usual. Variable definitions were consistent with previous
analyses [1].
Overall, of the 1 585 baseline VIDUS participants, 341
(21.5%) reported having an abscess in the last six months.
The factors associated with having an abscess at p < 0.1 in
univariate analyses included: female gender (OR = 2.4,
[95%CI: 1.8 – 3.0]; p < 0.001); unstable housing (OR =
1.3, [95%CI: 1.1 – 1.8]; p = 0.01); recent incarceration
(OR = 1.7, [95%CI: 1.3 – 2.1]; p < 0.001); sex trade
involvement (OR = 2.4, [95%CI: 1.9 – 3.1]; p < 0.001);
frequent heroin use (OR = 1.4, [95%CI: 1.1 – 1.8]; p =
0.006); frequent cocaine use (OR = 1.9, [95%CI: 1.5 –
2.5]; p < 0.001); residing in Vancouver's Downtown East-
side (OR = 1.5, [95%CI: 1.1 – 1.9]; p = 0.003); and HIV
serostatus (OR = 1.8, [95%CI: 1.4 – 2.3]; p < 0.001). Table
1 shows the baseline demographic characteristics of IDU
stratified by having an abscess or not in the past six
Table 1: Baseline demographic characteristics of IDU stratified by having an abscess in the past six months.
Characteristic No abscess past six 
months n = 1 244
Abscess past six 
months n = 341
Odds Ratio (95% CI) p-value
Gender
Male 848 (68.2) 162 (47.5)
Female 396 (31.8) 179 (52.5) 2.4 (1.9 – 3.0) < 0.001
HIV status
Negative 919 (73.9) 209 (61.3)
Positive 325 (26.1) 132 (38.7) 1.7 (1.4 – 2.3) < 0.001
Unstable housing*
No 492 (39.5) 109 (32.0)
Yes 752 (60.5) 387 (68.0) 1.3 (1.1 – 1.8) 0.011
Recent incarceration*
No 861 (69.2) 196 (57.5)
Yes 383 (30.8) 145 (42.5) 1.7 (1.3 – 2.1) <0.001
DTES residence*
No 552 (44.4) 121 (35.5)
Yes 692 (55.6) 220 (64.5) 1.5 (1.1 – 1.9) 0.003
Sex trade involved*
No 942 (75.7) 191 (56.0)
Yes 302 (24.3) 150 (44.0) 2.4 (1.9 – 3.1) < 0.001
Heroin use*
Less than daily 840 (67.5) 203 (59.5)
Daily use 404 (32.5) 138 (40.5) 1.4 (1.1 – 1.8) 0.006
Cocaine use*
Less than daily 858 (69.0) 182 (53.4)
Daily use 386 (31.0) 159 (46.6) 1.9 (1.5 – 2.5) < 0.001
Note: IDU = injection drug user, DTES = Downtown Eastside Residence. *Indicates behaviour during the six month period prior to the baseline 
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iate analysis.
As shown in Table 2, in a logistic regression model that
adjusted for all variables that were associated with having
an abscess at p < 0.1 in univariate analyses, female gender
[odds ratio (OR) = 1.7, [95% CI: 1.2 – 2.4]; p = 0.002),
recent incarceration (OR = 1.7, [95% CI: 1.3 – 2.2]; p <
0.001), sex trade involvement (OR = 1.4 [95% CI: 1.0 –
2.0]; p = 0.030), frequent cocaine use (OR = 1.5 [95% CI:
1.2 – 2.0]; p = 0.002) and HIV serostatus (OR = 1.5, [95%
CI: 1.2 – 2.0]; p = 0.003) were independently and posi-
tively associated with having an abscess.
Our results indicate female gender, recent incarceration,
sex trade involvement, frequent cocaine use and HIV
serostatus are positively associated with developing an
abscess. These results are consistent with results from a
study in Amsterdam where female gender and prostitu-
tion among women, as well as, frequent cocaine use were
identified as independently and positively associated with
skin abscesses [10]. In addition, the association between
HIV-positive status and having an abscess has been noted
elsewhere, and is understandable given that HIV-positive
individuals may have a heightened susceptibility to bacte-
rial infections [11,12]. Furthermore, high risk of infec-
tious complications, such as endocarditis from abscesses
[10], occur among HIV infected individuals [11].
Abscesses are a common consequence of injection drug
use [13-15]. The present study demonstrates that wide-
spread access to sterile syringes through high-volume nee-
dle exchanges and a medically supervised safer injection
facility may not be sufficient to prevent high rates of
abscesses among IDU in Vancouver. In addition, our find-
ings demonstrate the need for educational and structural
interventions to improve rates of sterile injecting [16,17].
Our study has limitations. First, although previous
research has indicated that the VIDUS cohort is represent-
ative of Vancouver IDU [18], VIDUS is not a random sam-
ple. Second, the study relied on self-report, and therefore,
the results could be susceptible to socially desirable
reporting although we know of no reason why reporting
abscesses would be subject to this concern. Third, the
cross-sectional nature of this study precludes any conclu-
sions regarding causal relationships between the variables
studied and the outcome of interest. Further prospective
study is needed to assess predictors of abscess in this set-
ting.
In summary, 21.5% of IDU participating in this study
reported having an abscess in the previous six months.
Results from this study indicate female gender, recent
incarceration, sex trade involvement, frequent cocaine use
and HIV serostatus are independently and positively asso-
ciated with developing an abscess in injection drug users.
Given the potential health complications arising from
bacterial infections our findings highlight the need for the
expansion of programs to promote safer injection prac-
tices.
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